phase

Robert Way Novartis (NYSE:NVS) said its oral drug iptacopan met the main goal of a phase 3 trial in certain patients with paroxysmal nocturnal hemoglobinuria (PNH) in a phase 3 trial. The study, dubbed APPOINT-PNH, evaluated iptacopan as a standalone therapy (200-mg twice daily) in adults with PNH who had […]